Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts.

Archives: Reports

MARA Rating Company
June 16, 2026

Tolebrutinib for in Adults With Non-Relapsing Secondary Progressive Multiple Sclerosis as of June 2026

MARA Rating Company June 16, 2026

Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment as of June 2026

MARA Rating Company June 16, 2026

Camizestrant for eR-Positive HER2-Negative Advanced Breast Cancer as of June 2026

MARA Rating Company June 16, 2026

Xocova for post-Exposure Prophylaxis of COVID-19 in Adults as of June 2026

MARA Rating Company June 16, 2026

Jascayd for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis as of June 2026

MARA Rating Company June 16, 2026

Tryngolza / olezarsen for familial Chylomicronemia Syndrome as of June 2026

MARA Rating Company June 16, 2026

Foundayo / orforglipron for managing overweight and obesity as of June 2026

MARA Rating Company June 16, 2026

Paltusotine for maintenance Treatment of Acromegaly in Adults as of June 2026

MARA Rating Company June 16, 2026

Pivekimab sunirine-pvzy for blastic plasmacytoid dendritic cell neoplasm as of June 2026

MARA Rating Company June 16, 2026

Redemplo / plozasiran for treating familial chylomicronemia syndrome as of June 2026

MARA Rating Company June 16, 2026